Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5152W HIGH $59.40
Volume
156.88 K
Value Traded
37.48 K
Short % Float
-
-25.76%Week
-43.34%1 Month
-81.52%3 Month
-86.3%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
473.58 K
EPS (TTM)
-103.95
P/E Ratio
-
Ent. Value
-9.82 M
Total Shares
1.03 M
Float Shares
-
Insiders
-
Institutions
1.61%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
BDRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Biodexa Pharmaceuticals plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Biodexa Pharmaceuticals plc
451Total events
3Upcoming
99Tier-1 (high impact)
2015 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseMTX240Corporate
Partnership with Syngene to manufacture MTX240 GMP clinical trial supplies
Gastrointestinal Stromal Tumors (GIST)source ↗
◆Topline ReadouteRapaClinical Data
Topline data expected from NMIBC Phase 2 study
Non-muscle Invasive Bladder Cancer (NMIBC)source ↗
▲Partnership / LicenseeRapaCorporate
Tanner Pharma Group and Biodexa announce strategic partnership for global early access program for eRapa in FAP
familiäre adenomatöse Polyposis (FAP)source ↗
▲Partnership / LicenseeRapaCorporate
Strategic partnership with Tanner Pharma Group for global early access program
Familial Adenomatous Polyposissource ↗
◆Enrollment UpdateeRapaTrial
Over 20% of patients enrolled in Phase 3 Serenta trial
Familial Adenomatous Polyposissource ↗
▲Partnership / LicenseMTX240Corporate
Biodexa licenses MTX240 from Otsuka
gastrointestinal stromal tumors (GIST)source ↗
▲Partnership / LicenseOPB-171775Corporate
Exclusive license of OPB-171775 (MTX240) from Otsuka
gastrointestinal stromal tumours (GIST)source ↗
◆Trial InitiationeRapaTrial
Nine additional European sites to activate
familial adenomatous polyposissource ↗
◆Enrollment UpdateeRapaTrial
Nine additional European sites to activate over next 2-3 months
familial adenomatous polyposis (FAP)source ↗
●Management ChangeCorporate
Fiona Sharp promoted to CFO and Company Secretary, elected to Board
▼Equity OfferingCorporate
Pricing of $10 million public offering of ADS Units and Pre-Funded Units
▲First Patient DosedeRapaTrial
First European patients enrolled in pivotal Phase 3 Serenta trial of eRapa in FAP
familial adenomatous polyposis (FAP)source ↗
▲Trial InitiationeRapaTrial
First European site activated for Phase 3 Serenta trial
familial adenomatous polyposissource ↗
▲EU MAA SubmissioneRapaEx-US Regulatory
CTA approved by EMA for Phase 3 Serenta trial in FAP
familial adenomatous polyposissource ↗
◆Oral PresentationPresentation
Breakfast symposium on FAP mechanisms and chemoprevention trial issues at CGA-IGC conference
Familial Adenomatous Polyposissource ↗
◆Enrollment MilestoneeRapaTrial
First European patient expected to be enrolled in 4Q 2025
familial adenomatous polyposissource ↗
◆Enrollment UpdateeRapaTrial
European sites expected to begin enrolling in Q4 2025
familial adenomatous polyposis (FAP)source ↗
▲First Patient DosedeRapaTrial
First patients enrolled in pivotal Phase 3 Serenta trial of eRapa in FAP
familial adenomatous polyposis (FAP)source ↗
▲Enrollment UpdateeRapaTrial
US enrollment began in August 2025
familial adenomatous polyposis (FAP)source ↗
▲First Patient DosedeRapaTrial
First patient enrolled in US component of Phase 3 Serenta trial
familial adenomatous polyposissource ↗
●EU MAA SubmissioneRapaEx-US Regulatory
CTA filed with EMA for Phase 3 Serenta trial
familial adenomatous polyposis (FAP)source ↗
▲Trial InitiationeRapaTrial
First clinical site opened in the US
familial adenomatous polyposis (FAP)source ↗
●EU MAA SubmissioneRapaEx-US Regulatory
Clinical Trial Application filed with EMA
Familial Adenomatous Polyposis (FAP)source ↗
▲Enrollment CompleteeRapaTrial
Phase 2 NMIBC study fully enrolled at 166 patients
Non-muscle Invasive Bladder Cancer (NMIBC)source ↗
▲Trial InitiationeRapaTrial
First clinical study site activated for Phase 3 Serenta trial
Familial Adenomatous Polyposis (FAP)source ↗
◆Quarterly UpdateCorporate
General Meeting to vote on share capital reorganisation and other resolutions
▲First Patient DosedtolimidoneTrial
First patient recruited in Phase 2 study of tolimidone in Type 1 Diabetes
Type 1 Diabetessource ↗
◆Trial InitiationeRapaTrial
Recruitment expected to begin in the next few weeks
familial adenomatous polyposissource ↗
▲First Patient DosedtolimidoneTrial
First patient enrolled in Phase 2a IIT of tolimidone
Type 1 Diabetes (T1D)source ↗
▲Milestone PaymentCorporate
CPRIT awards additional $3.0M grant for eRapa Phase 3 program in FAP
▲EU Orphan DesignationeRapaEx-US Regulatory
EC grants Orphan Drug Designation for eRapa in FAP
familial adenomatous polyposis (FAP)source ↗
▲EU Orphan DesignationeRapaEx-US Regulatory
Orphan Drug Designation granted by European Commission
Familial Adenomatous Polyposis (FAP)source ↗
◆Trial InitiationeRapaTrial
Initiation of registrational Phase 3 study of eRapa in FAP expected next quarter
familial adenomatous polyposissource ↗
◆Topline ReadouteRapaClinical Data
Phase 2 study in NMIBC expected to read out
Non-muscle Invasive Bladder Cancer (NMIBC)source ↗
▲Type C MeetingeRapaFDA Meeting
Successful Type C meeting with FDA regarding Phase 3 program for eRapa in FAP
familial adenomatous polyposissource ↗
▲Patent GrantedeRapaIP / Competition
U.S. patent allowed for oral rapamycin nanoparticle preparations
Familial Adenomatous Polyposissource ↗
▲Fast Track DesignationeRapaDesignation
FDA grants Fast Track designation for eRapa in FAP
Familial Adenomatous Polyposissource ↗
▲Fast Track DesignationeRapaDesignation
Fast Track designation for eRapa in FAP
Familial Adenomatous Polyposis (FAP)source ↗
●Type C MeetingeRapaFDA Meeting
Type C meeting with FDA to finalize protocol
Familial Adenomatous Polyposis (FAP)source ↗
Past FDA Catalysts and PDUFA Decisions
How BDRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2016-12-31 | MTX102 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D29 / 100
Pipeline Score
$3M
Pipeline Value
Undervalued
Valuation Signal
4
Drugs Scored
5.4x
rNPV / MCap
Top 71%
Micro Cap(rank 467 of 658)
Percentile Rank
Biodexa Pharmaceuticals plc faces pipeline headwinds (29/100), with $260M risk-adjusted pipeline value, led by Treatment with MTX110 in Medulloblastoma (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment with MTX110 UnknownCompletedNCT04315064 | Medulloblastoma | Phase 1 | COMPLETED | 2 | May 2, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every BDRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| MTX110 Fast Track | recurrent glioblastoma | Phase 1 | 2024-10-04 | Overall survival (OS) since start of treatment of 12 months and 13 months for Patients #1 and #2, respectively.; Patient #3 had progression free survival (PFS) of six months and OS thus far of 13 months since start of treatment.; Patient #4 has PFS and OS of 12 months since start of treatment.Read More | Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent GlioblastomaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BDRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BDRX for Q2 2026. | ||||
BDRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BDRX ranks across every disease it competes in
Competitive Position is a premium feature
See how BDRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBDRX News
-BDRX
Sep 15, 2026▲ +18.8%on this news· ran to -35% by day 3
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
Biodexa Pharmaceuticals has entered into a warrant exercise agreement with an accredited investor, generating approximately $2.3 million in gross proceeds. The agreement involves the exercise of existing warrants for American Depositary Shares at an exercise price of $1.05. In return, the investor will receive new warrants for additional shares, enhancing Biodexa's financial resources for its clinical programs.
Read more →-BDRX
Sep 11, 2026▼ -13.8%on this news· ran to -38% by day 3shared move
Interim results for the six months ended June 30, 2026
Biodexa Pharmaceuticals PLC reported its interim results for the six months ending June 30, 2026, highlighting operational advancements such as the in-licensing of MTX240 and the launch of an Early Access Program for eRapa. Financially, the company faced increased R&D costs and significant cash outflows, raising concerns about its future viability. Despite these challenges, the CEO expressed optimism regarding trial enrollments and the potential of their pipeline.
Read more →-BDRX
Aug 19, 2026▼ -9.4%on this news
Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
Biodexa Pharmaceuticals has announced a significant milestone in its Phase 3 trial for eRapa, having recruited 87 out of the planned 168 subjects. The trial, aimed at treating Familial Adenomatous Polyposis (FAP), is being conducted across 29 clinical sites in the US and Europe. The company plans a futility analysis after 25 Progression Free Survival events.
Read more →-BDRX
Jul 29, 2026Result of General Meeting
Biodexa Pharmaceuticals PLC announced the successful passing of all four resolutions at its General Meeting. The resolutions include a share reorganization that reduces the number of ordinary shares while maintaining their nominal value. Additionally, the directors have been granted authority to allot ordinary shares on a non-pre-emptive basis. This move supports the company's ongoing development of innovative cancer treatments.
Read more →-BDRX
Jul 29, 2026Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France
Biodexa Pharmaceuticals has initiated support activities for Familial Adenomatous Polyposis (FAP) patients in France, including a round table meeting in Paris. The company aims to enhance patient outcomes and has made its investigational drug eRapa available through an Early Access Program. A Phase 3 trial for eRapa is planned, supported by a $20 million grant.
Read more →-BDRX
Jun 30, 2026Result of Annual General Meeting
Biodexa Pharmaceuticals PLC held its Annual General Meeting where ordinary resolutions 1 through 7 passed with significant majorities. However, resolutions 8 and 10 failed, leading to the failure of resolution 11, which was contingent on resolution 8. Despite some setbacks, the company remains focused on developing treatments for gastrointestinal cancers and other diseases.
Read more →-BDRX
Jun 30, 2026Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants
Biodexa Pharmaceuticals has announced a $3.5 million registered direct offering and concurrent private placement. The offerings include American depositary shares and pre-funded warrants, with proceeds expected to fund development programs and working capital. The offerings are set to close on July 1, 2026, pending shareholder approval.
Read more →-BDRX
Jun 29, 2026Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
Biodexa Pharmaceuticals has received approval from Health Canada to expand its Phase 3 Serenta trial for familial adenomatous polyposis (FAP) into Canada. The trial, which is already active in the US and Europe, aims to enroll 168 patients, with 73 enrolled so far. The expansion is expected to enhance enrollment and provide a therapeutic option for FAP patients.
Read more →-BDRX
Jun 17, 2026Postponement and Re-scheduling of Annual General Meeting
Biodexa Pharmaceuticals PLC has postponed its Annual General Meeting (AGM) originally scheduled for June 17, 2026, due to a lack of quorum. The AGM has been rescheduled for June 30, 2026. Proxies submitted for the original meeting will remain valid for the rescheduled date.
Read more →-BDRX
May 14, 2026▼ -8.5%on this news
Biodexa issues letter to Shareholders
Biodexa Pharmaceuticals PLC has issued a letter to shareholders detailing proposals for reorganizing the company's share capital at the upcoming Annual General Meeting (AGM). The changes are intended to simplify the existing complex structure of ordinary shares while ensuring that shareholder rights and the number of American Depositary Shares (ADSs) remain unchanged. The AGM will take place on June 17, 2026, where several resolutions, including a reverse stock split and share reclassification, will be proposed. The Board recommends voting in favor of these resolutions to facilitate the capital restructuring.
Read more →-BDRX
Apr 2, 2026▲ +42.2%on this news
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
Biodexa Pharmaceuticals has announced a partnership with Syngene International to manufacture GMP clinical trial supplies for its drug MTX240. This collaboration marks the second time Syngene has worked with Biodexa, demonstrating their efficiency and flexibility in production timelines. MTX240 utilizes a novel mechanism of action that could address treatment-resistant gastrointestinal stromal tumors (GIST). Biodexa is planning to file an Investigational New Drug application and begin a Phase 1b/2a trial later this year, which will potentially benefit GIST patients who have exhausted existing treatment options.
Read more →-BDRX
Mar 31, 2026Tanner Pharma Group und Biodexa starten globales Early-Access-Programm für FAP-Patienten
Tanner Pharma Group and Biodexa Pharmaceuticals have announced a strategic partnership to launch a global Early-Access Program for eRapa, targeting patients with familial adenomatous polyposis (FAP). This program will allow clinicians to prescribe this investigational therapy outside of clinical trials, addressing a significant unmet medical need. The initiative will also generate real-world data to enhance understanding of FAP and patient experiences.
Read more →-BDRX
Mar 31, 2026Resumen: Tanner Pharma Group y Biodexa lanzan un programa de acceso anticipado global para pacientes de poliposis adenomatosa familiar
Tanner Pharma Group and Biodexa Pharmaceuticals have announced a strategic alliance to provide global access to eRapa for patients with familial adenomatous polyposis (FAP). This initiative aims to address the lack of approved therapeutic options for FAP, which typically manifests in adolescence. eRapa, an oral formulation of rapamycin, targets cellular processes involved in tumorigenesis.
Read more →-BDRX
Mar 31, 2026Riassunto: Tanner Pharma Group e Biodexa lanciano il programma globale di accesso anticipato per i pazienti affetti da FAP
Tanner Pharma Group and Biodexa Pharmaceuticals have partnered to launch a global access program for eRapa, aimed at patients with familial adenomatous polyposis (FAP). This condition, characterized by polyp proliferation in the colon and rectum, currently lacks an approved therapeutic option. eRapa, an oral formulation of sirolimus, targets mTOR pathways involved in cell growth and proliferation.
Read more →-BDRX
Mar 31, 2026Samenvatting: Tanner Pharma Group en Biodexa lanceren wereldwijd programma voor vroegtijdige toegang voor FAP-patiënten
Tanner Pharma Group and Biodexa Pharmaceuticals have announced a strategic partnership to provide global access to eRapa for patients with familial adenomatous polyposis (FAP). FAP is characterized by excessive polyp growth in the colon and rectum, and currently lacks an approved treatment. eRapa, an oral formulation of rapamycin, may offer a new therapeutic option.
Read more →-BDRX
Mar 27, 2026▼ -6.5%on this news· ran to +34% by day 3shared move
Preliminary Results for the Year Ended 31 December 2025
Biodexa Pharmaceuticals PLC announced its preliminary results for the year ended December 31, 2025, highlighting the initiation of the Phase 3 Serenta trial for eRapa in Familial Adenomatous Polyposis (FAP). The company also secured a licensing agreement for MTX240 from Otsuka, focusing on gastrointestinal cancers. Despite these advancements, Biodexa reported a loss of £6.38 million and faces challenges in securing further financing.
Read more →-BDRX
Mar 23, 2026Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group
Biodexa Pharmaceuticals has partnered with Tanner Pharma Group to launch a Global Early Access Program for eRapa, aimed at patients with Familial Adenomatous Polyposis (FAP). This program allows clinicians to prescribe eRapa outside of clinical trials, addressing a critical need for FAP patients who currently have no approved therapeutic options. Biodexa will also collect Real World Data to enhance understanding of FAP patient challenges.
Read more →-BDRX
Mar 18, 2026▼ -10.9%on this newsshared move
ADR Ratio Change
Biodexa Pharmaceuticals PLC announced a change in its American Depositary Receipts (ADR) ratio, effective around April 6, 2026. The new ratio will be one ADR for every 500,000 ordinary shares, aimed at meeting Nasdaq's $1.00 minimum bid price requirement. Existing ADR holders will need to exchange their old ADRs for new ones, with no fractional ADRs allocated.
Read more →-BDRX
Mar 9, 2026Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
Biodexa Pharmaceuticals has announced its support for the Life's a Polyp Foundation, the first U.S. advocacy group dedicated to patients with Familial Adenomatous Polyposis (FAP). The foundation aims to empower FAP patients through resources and community support. Biodexa's lead program, eRapa, is currently in a Phase 3 trial, representing a potential non-surgical treatment option for FAP.
Read more →-BDRX
Feb 19, 2026Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
Biodexa Pharmaceuticals has licensed MTX240, a Phase 1 ready drug candidate targeting gastrointestinal stromal tumors (GIST). This novel treatment utilizes a unique molecular glue mechanism, potentially benefiting patients with TKI-resistant disease. The company plans to initiate a Phase 1b/2a study by year-end, focusing on high-need populations.
Read more →About Biodexa Pharmaceuticals plc
HeadquartersCardiff
Founded2000
BIOPHARMAWATCH ELITE PLUS
Trade the next BDRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime